Renata’s heartburn tablet Esomeprazole MUPS secures UK marketing authorisation

Renata PLC has received marketing authorisation for Esomeprazole 20 mg and 40 mg heartburn tablets in the United Kingdom, as approved by the UK’s Medicines and Healthcare products Regulatory Agency.

The drug, popularly known as Maxpro MUPS in Bangladesh, is indicated for the management of gastroesophageal reflux disease, the treatment of erosive reflux esophagitis, and the treatment of Zollinger–Ellison Syndrome, the company said in a press release.

Additionally, the gastro‑resistant formulation prevents early degradation of the product, allowing proper release of the drug at its designated site of absorption.

Consequently, this translates into improved efficacy and tolerability for patients.

Renata pioneered the introduction of MUPS technology in Bangladesh, transforming the local Esomeprazole market by setting new benchmarks in formulation efficiency and therapeutic reliability.

Maxpro and Maxpro MUPS are Renata’s largest‑selling products in Bangladesh and, over the years, have become leading brands of Esomeprazole, trusted by healthcare professionals and consumers alike for their proven efficacy and consistent quality.